Erasca, Inc. ( ERAS) - Key Metrics
ERAS Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0 | -$0.14 | -$0.09 | -$0.09 |
| 2026Q1 | $0 | -$0.60 | -$0.09 | -$0.09 |
| 2025Q4 | $0 | -$0.10 | -$0.08 | -$0.08 |
| 2025Q3 | $0 | -$0.11 | -$0.08 | -$0.08 |
| 2025Q2 | $0 | -$0.12 | -$0.07 | -$0.07 |
ERAS Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -32.71 |
| 2026Q1 | 0% | -6.74 |
| 2025Q4 | 0% | -9.30 |
| 2025Q3 | 0% | -4.95 |
| 2025Q2 | 0% | -2.65 |
ERAS
Price: $18.38
52 week price:
Earnings Per Share: -0.96 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 393750
Market Capitalization: 6.5 billion